Medexus Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Medexus Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $6.71. The average 1-year stock price forecast is 67.75% higher than the current stock price, while the lowest is $5.55 (+38.75%) and the highest is $8.00 (+100.00%).

Price Target: $6.71 (+67.75%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$5.55	$6.71	$6.00	$8.00
Change	+38.75%	+67.75%	+50.00%	+100.00%

* Price targets were last updated on Feb 13, 2026.

Analyst Ratings

The average analyst rating for Medexus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Apr '26	May '26
Strong Buy	6	5	5	5	5	5
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	5	5	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Martin PhD Bloom Burton	Bloom Burton	Buy Maintains $6.00	Buy	Maintains	$6.00	+50.00%	Feb 13, 2026

Financial Forecast

Revenue This Year

99.88M

from 108.33M

-7.80%

from 108.33M

Revenue Next Year

114.09M

from 99.88M

14.23%

from 99.88M

EPS This Year

0.15

from 0.20

-20.76%

from 0.20

EPS Next Year

0.39

from 0.15

153.99%

from 0.15

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026
Revenue	79.66M	76.70M	108.10M	113.05M	108.33M	99.88M
Revenue Growth	43.52%	-3.72%	40.93%	4.59%	-4.18%	-7.80%
Gross Profit	47.48M	43.67M	65.77M	65.07M	63.51M	58.79M
Gross Margin	59.60%	56.94%	60.84%	57.56%	58.62%	58.86%
Operating Income	731.00K	-12.38M	8.49M	12.79M	11.92M	4.69M
Net Income	-28.26M	-2.88M	1.22M	-214.00K	2.25M	101.72K
EPS	-	-	-	-	0.20	0.15
EPS Growth	-	-	-	-	642.16%	-20.76%
Forward PE	-	-	-	-	-	18.51
Free Cash Flow	-8.96M	-10.18M	-8.98M	8.47M	28.32M	-6.47M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	100.8M
Avg	99.9M
Low	99.3M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-6.9%
Avg	-7.8%
Low	-8.4%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	0.15
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-20.8%
Low	-